Aduhelm

Chemical Nameaducanumab-avwa
Dosage FormInjection (intravenous; 170 mg/1.7 mL, 300 mg/3 mL)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyBiogen
Approval Year2021

Indication

  • For the treatment of Alzheimer’s disease
Last updated on 5/2/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Aduhelm (aducanumab-avwa) Prescribing Information.2022Biogen Inc., Cambridge, MA